Terms: = Ovarian cancer AND FOXA1, TCF3A, 3169, ENSG00000129514, P55317, HNF3A, MGC33105 AND Diagnosis
4 results:
1. Systematic Pan-cancer Analysis and Experimental Verification Identify foxa1 as an Immunological and Prognostic Biomarker in Epithelial ovarian cancer.
Wang K; Guan C; Yu J; Chen X; Shang X; Mei S; Feng X; Zheng L
Dis Markers; 2022; 2022():9328972. PubMed ID: 36393971
[TBL] [Abstract] [Full Text] [Related]
2. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM; Cobb LP; Westin SN; Zhang Y; Jazaeri A; Malpica A; Sun CC
Gynecol Oncol; 2022 Nov; 167(2):139-145. PubMed ID: 36137845
[TBL] [Abstract] [Full Text] [Related]
3. Effects of forkhead Box protein A1 on cell proliferation regulating and EMT of cervical carcinoma.
Gu F; Li ZH; Wang CQ; Yuan QF; Yan ZM
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7189-7196. PubMed ID: 30468461
[TBL] [Abstract] [Full Text] [Related]
4. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
[TBL] [Abstract] [Full Text] [Related]
